MiMedx Group, Inc. (NASDAQ:MDXG) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. raised its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 299.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,027,738 shares of the company's stock after purchasing an additional 770,744 shares during the quarter. Harbor Capital Advisors Inc. owned 0.70% of MiMedx Group worth $6,074,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. ProShare Advisors LLC grew its holdings in MiMedx Group by 8.5% during the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company's stock worth $160,000 after acquiring an additional 1,631 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of MiMedx Group by 1.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company's stock valued at $1,082,000 after purchasing an additional 1,822 shares in the last quarter. Hsbc Holdings PLC lifted its stake in shares of MiMedx Group by 7.3% in the 2nd quarter. Hsbc Holdings PLC now owns 34,343 shares of the company's stock valued at $233,000 after purchasing an additional 2,329 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in MiMedx Group by 7.6% during the second quarter. The Manufacturers Life Insurance Company now owns 45,623 shares of the company's stock worth $316,000 after buying an additional 3,222 shares in the last quarter. Finally, Marshall Wace LLP grew its position in MiMedx Group by 1.1% during the second quarter. Marshall Wace LLP now owns 298,818 shares of the company's stock valued at $2,071,000 after buying an additional 3,223 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Price Performance

MDXG traded up $0.20 on Monday, hitting $7.13. 1,327,702 shares of the company's stock were exchanged, compared to its average volume of 713,482. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.27. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of 12.60 and a beta of 1.94. The company has a current ratio of 4.10, a quick ratio of 3.22 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $6.06 and a 200-day moving average price of $6.67.

Analysts Set New Price Targets

MDXG has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $11.00 target price on shares of MiMedx Group in a research note on Thursday, August 1st. Craig Hallum lowered their price target on MiMedx Group from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Finally, StockNews.com upgraded MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, MiMedx Group has an average rating of "Buy" and a consensus price target of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.